Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1143

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1143
---
Symetrics, which may adversely impact their operations and financial condition.

Renovaro
Cube’s and BioSymetrics’ business and results of operations will suffer if it fails to compete effectively.

The testing
and diagnostic products industry is intensely competitive. Renovaro Cube has competitors both in Europe and abroad, including Grail, Inc.,
Exact Sciences Corporation, Freenome, Inc. and Thrive Earlier Detection Corp., that have stated that they are developing tests designed
to detect cancer. Similarly, there are companies with comparable and possibly competing offerings to BioSymetrics, including Recursion
Pharma, insitro, and In Silico Medicine. Each of these potential competitors have, or may have, substantially greater financial, technical
and other resources, such as larger research and development staff and well-established marketing and sales forces, and they
may operate in jurisdictions where lower standards of evidence are required to bring products to market. These competitors may succeed
in developing, acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than
Renovaro Cube’s or BioSymetrics’ products. In addition, established medical technology, biotechnology, or pharmaceutical companies
may invest heavily to accelerate the discovery and development of tests that could make Renovaro Cube’s or BioSymetrics’ products
less competitive than Renovaro anticipated.

Renovaro
Cube’s and BioSymetrics’ ability to compete successfully will depend largely on the ability of each to:

    ●
    successfully commercialize its products;

    ●
    demonstrate compelling advantages in the performance and convenience of its products, including on a cost-competitive basis;

    ●
    achieve market acceptance of its products by consumers, including self-insured employers, integrated health systems, healthcare providers and patients;

28

    ●
    achieve adequate coverage or reimbursement by third-party payors for its products;

    ●
    differentiate its product from the other tests and products of current and potential competitors;

    ●
    attract qualified scientific, data science, clinical development, product development and commercial personnel;

    ●
    obtain, maintain, defend and enforce patents and other intellectual property rights and claims as necessary for its products;

    ●
    obtain and maintain any necessary or desirable clearance or approval from regulators in Europe, the United Kingdom, the United States and other jurisdictions;

    ●
    successfully collaborate with institutions in the discovery, development and commercialization of its products; and

    ●